Diomidis Botsikas1, Anastasia Kalovidouri2, Minerva Becker2, Michele Copercini2, Dahila Amal Djema2, Alexandre Bodmer3, Sindy Monnier4, Christoph D Becker2, Xavier Montet2, Benedicte M A Delattre2, Osman Ratib5, Valentina Garibotto5, Claire Tabouret-Viaud5. 1. Department of Imaging, Division of Radiology, Geneva University Hospital, Rue Gabrielle-Perret-Gentil 4, 1205, Geneva, Switzerland. diomidis.botsikas@hcuge.ch. 2. Department of Imaging, Division of Radiology, Geneva University Hospital, Rue Gabrielle-Perret-Gentil 4, 1205, Geneva, Switzerland. 3. Department of Internal Medicine, Division of Oncology, Geneva University Hospital, Rue Gabrielle-Perret-Gentil 4, 1205, Geneva, Switzerland. 4. Department of Obstetrics and Gynaecology, Division of Gynaecology, Geneva University Hospital, Boulevard de la Cluse 30, 1211, Geneva, Switzerland. 5. Department of Imaging, Division of Nuclear Medicine, Geneva University Hospital, Rue Gabrielle-Perret-Gentil 4, 1205, Geneva, Switzerland.
Abstract
OBJECTIVE: To evaluate the performance of 18F-fluorodeoxyglucose (FDG) positron emission tomography magnetic resonance imaging (PET/MR) for preoperative breast cancer staging. METHODS: Preoperative PET/MR exams of 58 consecutive women with breast cancer were retrospectively reviewed. Histology and mean follow-up of 26 months served as gold standard. Four experienced readers evaluated primary lesions, lymph nodes and distant metastases with contrast-enhanced MRI, qualitative/quantitative PET, and combined PET/MR. ROC curves were calculated for all modalities and their combinations. RESULTS: The study included 101 breast lesions (83 malignant, 18 benign) and 198 lymph node groups, (34 malignant, 164 benign). Two patients had distant metastases. Areas under the curve (AUC) for breast cancer were 0.9558, 0.8347 and 0.8855 with MRI, and with qualitative and quantitative PET/MR, respectively (p = 0.066). Sensitivity for primary cancers with MRI and quantitative PET/MR was 100 % and 77 % (p = 0.004), and for lymph nodes 88 % and 79 % (p = 0.25), respectively. Specificity for MRI and PET/MR for primary cancers was 67 % and 100 % (p = 0.03) and for lymph nodes 98 % and 100 % (p = 0.25). CONCLUSIONS: In breast cancer patients, MRI alone has the highest sensitivity for primary tumours. For nodal metastases, both MRI and PET/MR are highly specific. KEY POINTS: • MRI alone and PET/MR have a similar overall diagnostic performance. • MRI alone has a higher sensitivity than PET/MR for local tumour assessment. • Both MRI and PET/MR have a limited sensitivity for nodal metastases. • Positive lymph nodes on MRI or PET/MR do not require presurgical biopsy.
OBJECTIVE: To evaluate the performance of 18F-fluorodeoxyglucose (FDG) positron emission tomography magnetic resonance imaging (PET/MR) for preoperative breast cancer staging. METHODS: Preoperative PET/MR exams of 58 consecutive women with breast cancer were retrospectively reviewed. Histology and mean follow-up of 26 months served as gold standard. Four experienced readers evaluated primary lesions, lymph nodes and distant metastases with contrast-enhanced MRI, qualitative/quantitative PET, and combined PET/MR. ROC curves were calculated for all modalities and their combinations. RESULTS: The study included 101 breast lesions (83 malignant, 18 benign) and 198 lymph node groups, (34 malignant, 164 benign). Two patients had distant metastases. Areas under the curve (AUC) for breast cancer were 0.9558, 0.8347 and 0.8855 with MRI, and with qualitative and quantitative PET/MR, respectively (p = 0.066). Sensitivity for primary cancers with MRI and quantitative PET/MR was 100 % and 77 % (p = 0.004), and for lymph nodes 88 % and 79 % (p = 0.25), respectively. Specificity for MRI and PET/MR for primary cancers was 67 % and 100 % (p = 0.03) and for lymph nodes 98 % and 100 % (p = 0.25). CONCLUSIONS: In breast cancerpatients, MRI alone has the highest sensitivity for primary tumours. For nodal metastases, both MRI and PET/MR are highly specific. KEY POINTS: • MRI alone and PET/MR have a similar overall diagnostic performance. • MRI alone has a higher sensitivity than PET/MR for local tumour assessment. • Both MRI and PET/MR have a limited sensitivity for nodal metastases. • Positive lymph nodes on MRI or PET/MR do not require presurgical biopsy.
Entities:
Keywords:
18F-FDG; Breast cancer; Magnetic resonance imaging (MRI); Positron emission tomography (PET); Whole body imaging
Authors: N H G M Peters; S van Esser; M A A J van den Bosch; R K Storm; P W Plaisier; T van Dalen; S C E Diepstraten; T Weits; P J Westenend; G Stapper; M A Fernandez-Gallardo; I H M Borel Rinkes; R van Hillegersberg; W P Th M Mali; P H M Peeters Journal: Eur J Cancer Date: 2010-12-30 Impact factor: 9.162
Authors: Christopher C Riedl; Elina Slobod; Maxine Jochelson; Monica Morrow; Debra A Goldman; Mithat Gonen; Wolfgang A Weber; Gary A Ulaner Journal: J Nucl Med Date: 2014-09-11 Impact factor: 10.057
Authors: Maria J Garcia-Velloso; Maria J Ribelles; Macarena Rodriguez; Alejandro Fernandez-Montero; Lidia Sancho; Elena Prieto; Marta Santisteban; Natalia Rodriguez-Spiteri; Miguel A Idoate; Fernando Martinez-Regueira; Arlette Elizalde; Luis J Pina Journal: Eur Radiol Date: 2016-12-21 Impact factor: 5.315
Authors: Amy M Fowler; Manoj Kumar; Leah Henze Bancroft; Kelley Salem; Jacob M Johnson; Jillian Karow; Scott B Perlman; Tyler J Bradshaw; Samuel A Hurley; Alan B McMillan; Roberta M Strigel Journal: Radiol Imaging Cancer Date: 2021-01-15